MADRID — Metformin is taken every day by more than 200 million people worldwide. Its value as a glucose-lowering agent has been established for decades. But does metformin hold similar promise for reducing rates of cardiovascular disease (CVD)? This question was the focus of a thought-provoking presentation by Simon Griffin…
